FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2323189596> ?p ?o ?g. }

• W2323189596 endingPage "1272" @default.
• W2323189596 startingPage "1266" @default.
• W2323189596 abstract "Preventing distant recurrence and achieving local control are important challenges in rectal cancer treatment, and use of adjuvant chemotherapy has been studied. However, no phase III study comparing adjuvant chemotherapy regimens for rectal cancer has demonstrated superiority of a specific regimen. We therefore conducted a phase III study to evaluate the superiority of S-1 to tegafur-uracil (UFT), a standard adjuvant chemotherapy regimen for curatively resected stage II/III rectal cancer in Japan, in the adjuvant setting for rectal cancer.The ACTS-RC trial was an open-label, randomized, phase III superiority trial conducted at 222 sites in Japan. Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year. The primary end point was relapse-free survival (RFS), and the secondary end points were overall survival and adverse events.In total, 961 patients were enrolled from April 2006 to March 2009. The primary analysis was conducted in 480 assigned to receive UFT and 479 assigned to receive S-1. Five-year RFS was 61.7% [95% confidence interval (CI) 57.1% to 65.9%] for UFT and 66.4% (95% CI 61.9% to 70.5%) for S-1 [P = 0.0165, hazard ratio (HR): 0.77, 95% CI 0.63-0.96]. Five-year survival was 80.2% (95% CI 76.3% to 83.5%) for UFT and 82.0% (95% CI 78.3% to 85.2%) for S-1. The main grade 3 or higher adverse events were increased alanine aminotransferase and diarrhea (each 2.3%) in the UFT arm and anorexia, diarrhea (each 2.6%), and fatigue (2.1%) in the S-1 arm.One-year S-1 treatment is superior to UFT with respect to RFS and has therefore become a standard adjuvant chemotherapy regimen for stage II/III rectal cancer following curative resection." @default.
• W2323189596 created "2016-06-24" @default.
• W2323189596 creator A5003621363 @default.
• W2323189596 creator A5004189669 @default.
• W2323189596 creator A5004420462 @default.
• W2323189596 creator A5010170854 @default.
• W2323189596 creator A5017230904 @default.
• W2323189596 creator A5021979476 @default.
• W2323189596 creator A5024742184 @default.
• W2323189596 creator A5026639791 @default.
• W2323189596 creator A5027118202 @default.
• W2323189596 creator A5063723368 @default.
• W2323189596 creator A5067072266 @default.
• W2323189596 creator A5072329283 @default.
• W2323189596 creator A5075771222 @default.
• W2323189596 creator A5081174788 @default.
• W2323189596 creator A5082936561 @default.
• W2323189596 creator A5084629531 @default.
• W2323189596 creator A5086205559 @default.
• W2323189596 date "2016-07-01" @default.
• W2323189596 modified "2023-10-17" @default.
• W2323189596 title "A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)" @default.
• W2323189596 cites W1880063947 @default.
• W2323189596 cites W2040872961 @default.
• W2323189596 cites W2041388963 @default.
• W2323189596 cites W2060125465 @default.
• W2323189596 cites W2097656606 @default.
• W2323189596 cites W2099764000 @default.
• W2323189596 cites W2100241851 @default.
• W2323189596 cites W2113353705 @default.
• W2323189596 cites W2119534563 @default.
• W2323189596 cites W2119598754 @default.
• W2323189596 cites W2124886112 @default.
• W2323189596 cites W2125016589 @default.
• W2323189596 cites W2132565869 @default.
• W2323189596 cites W2147297736 @default.
• W2323189596 cites W2167138718 @default.
• W2323189596 cites W2171232394 @default.
• W2323189596 cites W2411552431 @default.
• W2323189596 doi "https://doi.org/10.1093/annonc/mdw162" @default.
• W2323189596 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4922318" @default.
• W2323189596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27056996" @default.
• W2323189596 hasPublicationYear "2016" @default.
• W2323189596 type Work @default.
• W2323189596 sameAs 2323189596 @default.
• W2323189596 citedByCount "37" @default.
• W2323189596 countsByYear W23231895962015 @default.
• W2323189596 countsByYear W23231895962016 @default.
• W2323189596 countsByYear W23231895962018 @default.
• W2323189596 countsByYear W23231895962019 @default.
• W2323189596 countsByYear W23231895962020 @default.
• W2323189596 countsByYear W23231895962021 @default.
• W2323189596 countsByYear W23231895962022 @default.
• W2323189596 countsByYear W23231895962023 @default.
• W2323189596 crossrefType "journal-article" @default.
• W2323189596 hasAuthorship W2323189596A5003621363 @default.
• W2323189596 hasAuthorship W2323189596A5004189669 @default.
• W2323189596 hasAuthorship W2323189596A5004420462 @default.
• W2323189596 hasAuthorship W2323189596A5010170854 @default.
• W2323189596 hasAuthorship W2323189596A5017230904 @default.
• W2323189596 hasAuthorship W2323189596A5021979476 @default.
• W2323189596 hasAuthorship W2323189596A5024742184 @default.
• W2323189596 hasAuthorship W2323189596A5026639791 @default.
• W2323189596 hasAuthorship W2323189596A5027118202 @default.
• W2323189596 hasAuthorship W2323189596A5063723368 @default.
• W2323189596 hasAuthorship W2323189596A5067072266 @default.
• W2323189596 hasAuthorship W2323189596A5072329283 @default.
• W2323189596 hasAuthorship W2323189596A5075771222 @default.
• W2323189596 hasAuthorship W2323189596A5081174788 @default.
• W2323189596 hasAuthorship W2323189596A5082936561 @default.
• W2323189596 hasAuthorship W2323189596A5084629531 @default.
• W2323189596 hasAuthorship W2323189596A5086205559 @default.
• W2323189596 hasBestOaLocation W23231895961 @default.
• W2323189596 hasConcept C121608353 @default.
• W2323189596 hasConcept C126322002 @default.
• W2323189596 hasConcept C141071460 @default.
• W2323189596 hasConcept C168563851 @default.
• W2323189596 hasConcept C197934379 @default.
• W2323189596 hasConcept C203092338 @default.
• W2323189596 hasConcept C207103383 @default.
• W2323189596 hasConcept C2776694085 @default.
• W2323189596 hasConcept C2777299880 @default.
• W2323189596 hasConcept C2777863537 @default.
• W2323189596 hasConcept C2778336483 @default.
• W2323189596 hasConcept C2781413609 @default.
• W2323189596 hasConcept C44249647 @default.
• W2323189596 hasConcept C526805850 @default.
• W2323189596 hasConcept C71924100 @default.
• W2323189596 hasConcept C90924648 @default.
• W2323189596 hasConceptScore W2323189596C121608353 @default.
• W2323189596 hasConceptScore W2323189596C126322002 @default.
• W2323189596 hasConceptScore W2323189596C141071460 @default.
• W2323189596 hasConceptScore W2323189596C168563851 @default.
• W2323189596 hasConceptScore W2323189596C197934379 @default.
• W2323189596 hasConceptScore W2323189596C203092338 @default.
• W2323189596 hasConceptScore W2323189596C207103383 @default.
• W2323189596 hasConceptScore W2323189596C2776694085 @default.
• W2323189596 hasConceptScore W2323189596C2777299880 @default.

• next